175 related articles for article (PubMed ID: 32821285)
1. Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response
Wasiak S; Gilham D; Daze E; Tsujikawa LM; Halliday C; Stotz SC; Rakai BD; Fu L; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Cardiovasc Ther; 2020; 2020():9397109. PubMed ID: 32821285
[TBL] [Abstract][Full Text] [Related]
2. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism.
Tsujikawa LM; Fu L; Das S; Halliday C; Rakai BD; Stotz SC; Sarsons CD; Gilham D; Daze E; Wasiak S; Studer D; Rinker KD; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Clin Epigenetics; 2019 Jul; 11(1):102. PubMed ID: 31300040
[TBL] [Abstract][Full Text] [Related]
3. BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes.
Wasiak S; Dzobo KE; Rakai BD; Kaiser Y; Versloot M; Bahjat M; Stotz SC; Fu L; Sweeney M; Johansson JO; Wong NCW; Stroes ESG; Kroon J; Kulikowski E
Clin Epigenetics; 2020 Nov; 12(1):166. PubMed ID: 33172487
[TBL] [Abstract][Full Text] [Related]
4. Apabetalone downregulates factors and pathways associated with vascular calcification.
Gilham D; Tsujikawa LM; Sarsons CD; Halliday C; Wasiak S; Stotz SC; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kalantar-Zadeh K; Kulikowski E
Atherosclerosis; 2019 Jan; 280():75-84. PubMed ID: 30476723
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells.
Wasiak S; Tsujikawa LM; Daze E; Gilham D; Stotz SC; Rakai BD; Sarsons CD; Fu L; Azhar S; Jahagirdar R; Sweeney M; Johansson JO; Wong NCW; Kulikowski E
Atherosclerosis; 2023 Jan; 364():10-19. PubMed ID: 36455344
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208).
Wasiak S; Gilham D; Tsujikawa LM; Halliday C; Calosing C; Jahagirdar R; Johansson J; Sweeney M; Wong NC; Kulikowski E
J Cardiovasc Transl Res; 2017 Aug; 10(4):337-347. PubMed ID: 28567671
[TBL] [Abstract][Full Text] [Related]
7. Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.
Kulikowski E; Halliday C; Johansson J; Sweeney M; Lebioda K; Wong N; Haarhaus M; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Kidney Blood Press Res; 2018; 43(2):449-457. PubMed ID: 29566379
[TBL] [Abstract][Full Text] [Related]
8. BET Epigenetic Reader Proteins in Cardiovascular Transcriptional Programs.
Borck PC; Guo LW; Plutzky J
Circ Res; 2020 Apr; 126(9):1190-1208. PubMed ID: 32324495
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.
Fu L; Wasiak S; Tsujikawa LM; Rakai BD; Stotz SC; Wong NCW; Johansson JO; Sweeney M; Mohan CM; Khan A; Kulikowski E
Pharmacol Res Perspect; 2022 Jun; 10(3):e00949. PubMed ID: 35417091
[TBL] [Abstract][Full Text] [Related]
10. The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1.
Mohammed SA; Albiero M; Ambrosini S; Gorica E; Karsai G; Caravaggi CM; Masi S; Camici GG; Wenzl FA; Calderone V; Madeddu P; Sciarretta S; Matter CM; Spinetti G; Lüscher TF; Ruschitzka F; Costantino S; Fadini GP; Paneni F
Antioxid Redox Signal; 2022 Apr; 36(10-12):667-684. PubMed ID: 34913726
[No Abstract] [Full Text] [Related]
11. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Toth PP; Schwartz GG; Nicholls SJ; Khan A; Szarek M; Ginsberg HN; Johansson JO; Kalantar-Zadeh K; Kulikowski E; Lebioda K; Wong NCW; Sweeney M; Ray KK;
Am J Prev Cardiol; 2022 Sep; 11():100372. PubMed ID: 36039183
[TBL] [Abstract][Full Text] [Related]
12. Apabetalone - BET protein inhibition in cardiovascular disease and Type 2 diabetes.
Brandts J; Ray KK
Future Cardiol; 2020 Sep; 16(5):385-395. PubMed ID: 32378426
[TBL] [Abstract][Full Text] [Related]
13. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
[TBL] [Abstract][Full Text] [Related]
14. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.
Belkina AC; Nikolajczyk BS; Denis GV
J Immunol; 2013 Apr; 190(7):3670-8. PubMed ID: 23420887
[TBL] [Abstract][Full Text] [Related]
15. Bromodomain and extraterminal domain-containing protein inhibition attenuates acute inflammation after spinal cord injury.
Rudman MD; Choi JS; Lee HE; Tan SK; Ayad NG; Lee JK
Exp Neurol; 2018 Nov; 309():181-192. PubMed ID: 30134146
[TBL] [Abstract][Full Text] [Related]
16. Role of STAT3 and C/EBP in cytokine-dependent expression of the mouse serum amyloid P-component (SAP) and C-reactive protein (CRP) genes.
Ochrietor JD; Harrison KA; Zahedi K; Mortensen RF
Cytokine; 2000 Jul; 12(7):888-99. PubMed ID: 10880233
[TBL] [Abstract][Full Text] [Related]
17. The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation.
Zhang XX; Lin J; Liang TZ; Duan H; Tan XH; Xi BM; Li L; Liu SW
Acta Pharmacol Sin; 2019 Jan; 40(1):98-110. PubMed ID: 29789664
[TBL] [Abstract][Full Text] [Related]
18. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease.
Haarhaus M; Ray KK; Nicholls SJ; Schwartz GG; Kulikowski E; Johansson JO; Sweeney M; Halliday C; Lebioda K; Wong N; Brandenburg V; Beddhu S; Tonelli M; Zoccali C; Kalantar-Zadeh K
Atherosclerosis; 2019 Nov; 290():59-65. PubMed ID: 31568963
[TBL] [Abstract][Full Text] [Related]
19. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.
Cummings J; Schwartz GG; Nicholls SJ; Khan A; Halliday C; Toth PP; Sweeney M; Johansson JO; Wong NCW; Kulikowski E; Kalantar-Zadeh K; Lebioda K; Ginsberg HN; Winblad B; Zetterberg H; Ray KK
J Alzheimers Dis; 2021; 83(4):1703-1715. PubMed ID: 34459400
[TBL] [Abstract][Full Text] [Related]
20. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes.
Febvre-James M; Lecureur V; Fardel O
Inflamm Res; 2020 Jan; 69(1):51-62. PubMed ID: 31654094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]